Potential therapies for the detrimental effects of prenatal exposure to THC have been discovered using a preclinical animal model.
A new study using a preclinical animal model suggests that prenatal cannabis exposure, specifically exposure to THC, the psychoactive component of cannabis, makes the brain’s dopamine neurons hyperactive and increases sensitivity to the behavioural effects of THC during pre-adolescence.
As a growing number of US states legalise the medicinal and recreational use of cannabis, an increasing number of American women are using cannabis before becoming pregnant and during early pregnancy often to treat morning sickness, anxiety, and lower back pain.
Prenatal cannabis exposure
Although emerging evidence indicates that this may have long-term consequences for their babies’ brain development, how this occurs remains unclear.
A University of Maryland School of Medicine study using a preclinical animal model suggests that prenatal exposure to THC, the psychoactive component of cannabis, makes the brain’s dopamine neurons (an integral component of the reward system) hyperactive and increases sensitivity to the behavioral effects of THC during pre-adolescence.
This may contribute to the increased risk of psychiatric disorders like schizophrenia and other forms of psychosis later in adolescence that previous research has linked to prenatal cannabis use, according to the study published today in journal Nature Neuroscience.
The team of researchers, from UMSOM, the University of Cagliari (Italy) and the Hungarian Academy of Sciences (Hungary), found that exposure to THC in the womb increased susceptibility to THC in offspring on several behavioural tasks that mirrors the effects observed in many psychiatric diseases.
These behavioural effects were caused, at least in part, by hyperactivity of dopamine neurons in a brain region called the ventral tegmental area (VTA), which regulates motivated behaviours.
The researchers were able to correct these behavioural problems and brain abnormalities by treating experimental animals with pregnenolone, an FDA-approved drug currently under investigation in clinical trials for cannabis use disorder, schizophrenia, autism, and bipolar disorder.
Joseph Cheer, PhD, a Professor of Anatomy & Neurobiology and Psychiatry at the University of Maryland School of Medicine, said: “This is an exciting finding that suggests a therapeutic approach for children born to mothers who used cannabis during pregnancy.
“It also raises important questions that need to be addressed such as how does pregnenolone exert its effects and how can we improve its efficacy? Do these detrimental effects persist into adulthood, and if so, could they also be treated in a similar way?”
The researchers concluded that as physicians caution pregnant women against alcohol and cocaine intake because of their detrimental effects to the foetus, they should also, based on these new findings, advise them on the potential negative consequences of using cannabis specifically during pregnancy.